Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMOXICILLIN PEDIATRIC vs AMOXICILLIN AND CLAVULANATE POTASSIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Treatment of infections caused by susceptible strains of microorganisms in conditions such as otitis media, sinusitis, pharyngitis, tonsillitis, pneumonia, bronchitis, urinary tract infections, skin and skin structure infections, and gonorrhea,Prophylaxis of infective endocarditis in patients undergoing dental or upper respiratory tract procedures (off-label but per ADA/AHA guidelines),Eradication of Helicobacter pylori (as part of combination therapy)
Lower respiratory tract infections,Acute bacterial sinusitis,Otitis media,Urinary tract infections,Skin and skin structure infections,Bone and joint infections,Intra-abdominal infections,Dental infections
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Amoxicillin is primarily metabolized by hydrolysis to penicilloic acid, which is then excreted renally. It does not undergo extensive hepatic metabolism; renal clearance involves tubular secretion and glomerular filtration.
Amoxicillin undergoes partial hepatic metabolism via hydrolysis. Clavulanate is extensively metabolized in the liver, primarily by hydrolysis and conjugation.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
17-20% bound to serum proteins, primarily albumin.
Amoxicillin: ~20% (mainly albumin); Clavulanate: ~25% (albumin).
0.3-0.5 L/kg; reflects distribution into extracellular fluid and well-perfused tissues; crosses placenta and distributes into pleural, synovial, and peritoneal fluids.
Amoxicillin: ~0.3-0.4 L/kg; Clavulanate: ~0.3 L/kg. Distributes into tissues, not CSF unless inflamed.
Oral: 75-90% (absorption is rapid but incomplete; food does not significantly affect absorption).
Oral: ~80-90% for amoxicillin; ~60-75% for clavulanate. Enhanced with food.
Cr Cl 10-30 m L/min: administer every 12 hours. Cr Cl <10 m L/min: administer every 24 hours. Hemodialysis: administer dose after dialysis.
For Cr Cl 10-30 m L/min: 250-500 mg amoxicillin component every 12 hours. For Cr Cl <10 m L/min: 250-500 mg amoxicillin component every 24 hours. Hemodialysis: 250-500 mg every 24 hours, give additional dose during and after dialysis.
No specific dose adjustment required for Child-Pugh A or B. Child-Pugh C: consider dose reduction based on clinical response.
No specific dose adjustment recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh C); consider alternative therapy or reduced dosing, but no formal guidelines.
Neonates <4 weeks: 30 mg/kg/day divided every 12 hours. Infants and children >4 weeks: 20-50 mg/kg/day divided every 8 hours (mild-moderate infection) up to 80-100 mg/kg/day divided every 6-8 hours (severe infection).
For children >3 months: 25-45 mg/kg/day of amoxicillin component divided every 12 hours (based on 200 mg/28.5 mg per 5 m L suspension) or 20-40 mg/kg/day divided every 8 hours (based on 125 mg/31.25 mg per 5 m L suspension). For severe infections, up to 90 mg/kg/day of amoxicillin component divided every 12 hours (using 400 mg/57 mg per 5 m L suspension).
No specific dose adjustment based solely on age; assess renal function and adjust accordingly due to age-related decline in GFR.
Initiate at lower end of dosing range due to increased risk of renal impairment. Monitor renal function and adjust dose based on creatinine clearance as per renal adjustment guidelines.
No FDA black box warning.
No FDA boxed warning.
Serious hypersensitivity reactions (anaphylaxis) may occur; discontinue therapy if allergic reaction occurs. Clostridium difficile-associated diarrhea (CDAD) can occur. Adjust dose in renal impairment. Use caution in patients with mononucleosis due to high incidence of morbilliform rash. Prolonged use may result in superinfection.
Hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome) in patients with penicillin allergy,Clostridioides difficile-associated diarrhea,Hepatic toxicity (elevated liver enzymes, hepatitis, cholestatic jaundice) more common in elderly and with prolonged use,Renal impairment requires dose adjustment,Risk of superinfection with prolonged therapy,Skin rash can occur in patients with mononucleosis
Hypersensitivity to amoxicillin or any penicillin derivative; history of anaphylactic reaction to beta-lactams.
History of anaphylactic reaction to penicillins or cephalosporins,Previous cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Concurrent use with disulfiram or probenecid (relative)
Amoxicillin absorption is not significantly affected by food; may be taken with or without meals. However, to minimize gastrointestinal upset, administer with a small amount of food if needed. Avoid acidic beverages (e.g., fruit juices) within 1 hour of dosing as they may degrade the antibiotic.
May be taken with or without food; food enhances absorption; avoid ingestion with high-dose clavulanate? (no significant interaction); no specific food restrictions; milk-containing products do not interact significantly.
Amoxicillin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Human data from pregnant women indicate no increased risk of major birth defects across all trimesters. Caution in first trimester due to limited data, but generally considered safe.
Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Use during first trimester is considered safe if clinically indicated. During second and third trimesters, no known fetal risks. However, avoid use near term due to potential for neonatal kernicterus (theoretical risk from high doses, but not confirmed).
Amoxicillin is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding; minimal risk of infant effects such as diarrhea or allergic sensitization. Monitor infant for potential gastrointestinal disturbances.
Amoxicillin and clavulanate are excreted into breast milk in low concentrations. M/P ratio not established. Considered compatible with breastfeeding by AAP; risk of infant sensitization, diarrhea, or thrush. Use with caution in infants with history of penicillin allergy.
Physiologic changes in pregnancy (increased renal blood flow, glomerular filtration rate, and volume of distribution) may lower serum concentrations. Standard dosing is generally adequate, but severe infections may require dose adjustment. No specific dose reduction recommended; monitor clinical response.
Pharmacokinetic changes in pregnancy (increased renal clearance, expanded plasma volume) may require dose adjustments: total daily dose typically remains same but dosing interval may need to be shortened (e.g., every 6-8 hours instead of every 12 hours) for severe infections; monitor clinical response. No standard recommendation for routine adjustment; base on severity and renal function.
Amoxicillin pediatric suspension is dosed based on body weight; typical dose is 20-40 mg/kg/day in divided doses every 8 hours. For high-dose therapy (e.g., resistant pneumococcus), 80-90 mg/kg/day in two divided doses. Shake suspension well before each dose. Use within 14 days after reconstitution; discard unused portion. Not for patients with severe renal impairment (Cr Cl <30 m L/min) without dose adjustment. Monitor for rash, diarrhea, and hypersensitivity reactions.
Use weight-based dosing for pediatric patients; reconstitute oral suspension with appropriate amount of water; administer at start of meal to reduce GI upset; check renal function before dosing; avoid in patients with mononucleosis due to risk of maculopapular rash; higher doses of clavulanate may cause diarrhea; intravenous infusion over 30-40 minutes; consider penicillin allergy cross-reactivity; not effective against MRSA; requires dose adjustment in Cr Cl <30 m L/min.
Take this medication exactly as prescribed; complete the full course even if your child feels better.,Shake the bottle well before each dose; measure the dose with the provided dosing device.,Refrigerate the suspension after mixing; do not freeze. Discard any unused portion after 14 days.,Do not give this medication if your child is allergic to penicillins or cephalosporins.,Common side effects include diarrhea, nausea, and rash. Contact your doctor if severe diarrhea or signs of allergic reaction occur.,This medication may reduce the effectiveness of oral contraceptives; use additional birth control if applicable.,Inform your doctor if your child has kidney disease, phenylketonuria (some suspensions contain phenylalanine), or is pregnant/breastfeeding.
Take this medication exactly as prescribed, usually every 12 hours.,Take with food to reduce stomach upset and improve absorption.,Complete the full course even if you feel better.,Shake the oral suspension well before each use.,Store oral suspension in refrigerator, discard after 10 days.,Report severe diarrhea, rash, or signs of allergy immediately.,May cause diarrhea; do not treat without consulting doctor.,Inform your doctor if you are pregnant, breastfeeding, or have liver disease.
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMOXICILLIN PEDIATRIC vs AMOXICILLIN AND CLAVULANATE POTASSIUM, answered by our medical review team.
AMOXICILLIN PEDIATRIC is a Penicillin Antibiotic that works by Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.. AMOXICILLIN AND CLAVULANATE POTASSIUM is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMOXICILLIN PEDIATRIC and AMOXICILLIN AND CLAVULANATE POTASSIUM depend on the specific clinical indication. These are both Penicillin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMOXICILLIN PEDIATRIC is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.. The standard adult dose of AMOXICILLIN AND CLAVULANATE POTASSIUM is: 500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining AMOXICILLIN PEDIATRIC and AMOXICILLIN AND CLAVULANATE POTASSIUM. Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. AMOXICILLIN PEDIATRIC is classified as Category A/B. Amoxicillin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Human data from pregnant women indicate no increased risk of major birth def. AMOXICILLIN AND CLAVULANATE POTASSIUM is classified as Category A/B. Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.